Comparison of lidocaine gel and methoxyflurane in cystoscopy

Comparison of lidocaine gel and methoxyflurane in relieving pain in patients scheduled to undergo elective cystoscopy

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201207253579N3

Enrollment

Registered

2012-12-12

Start date

2012-12-15

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Analgesic effect of methoxyflurane and lidocaine gel during cystoscopy. Inhaled anesthetics local anesthetics

Interventions

Intervention 1: Methoxyflurane is a volatile fluorinated hydrocarbon anesthetic agent that is available with 3 CC ampoules to be used in a penthrox inhaler. The inhaler is primed with 3 CC methox

Prevention

Treatment - Drugs

Methoxyflurane is a volatile fluorinated hydrocarbon anesthetic agent that is available with 3 CC ampoules to be used in a penthrox inhaler. The inhaler is primed with 3 CC methoxyflurane. The i

Fifteen minutes before the procedure 20 cc lidocaine gel 2% is administered.

In each step of the study if pain score is more than 4 (utilizing VAS) we will administer 10 microgram/kg alfentanyl.

Eligibility

Sex/Gender

Male

Age

20 Years to 55 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients with American Society of Anesthesiologists Physical Status Classification (ASA class) I and II scheduled to undergo elective cystoscopy and their age is between 20-55 years old. Exclusion criteria: Allergy to lidocaine and methoxyflurane, concurrent use of analgesics in recent 24 hours, age>55 years old, addiction, renal failure, neuropathy, liver disease, pregnancy.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Pain. Timepoint: Before entrance, at the time of drug administration, just at the instrument insertion, during bladder examination, end of procedure and 15 minutes after operation. Method of measurement: standard visual analog scale.	—

Secondary

Measure	Time frame
Heart rate. Timepoint: Before entrance, at the time of drug administration, just at the instrument insertion, during bladder examination, end of procedure and 15 minutes after operation. Method of measurement: Electrocardiography monitoring.;Blood pressure. Timepoint: Before entrance, at the time of drug administration, just at the instrument insertion, during bladder examination, end of procedure and 15 minutes after operation. Method of measurement: Noninvasive blood pressure.;Blood oxygen saturation. Timepoint: Before entrance, at the time of drug administration, just at the instrument insertion, during bladder examination, end of procedure and 15 minutes after operation. Method of measurement: Pulse Oxymetry.	—

Measure

Time frame

Heart rate. Timepoint: Before entrance, at the time of drug administration, just at the instrument insertion, during bladder examination, end of procedure and 15 minutes after operation. Method of measurement: Electrocardiography monitoring.;Blood pressure. Timepoint: Before entrance, at the time of drug administration, just at the instrument insertion, during bladder examination, end of procedure and 15 minutes after operation. Method of measurement: Noninvasive blood pressure.;Blood oxygen saturation. Timepoint: Before entrance, at the time of drug administration, just at the instrument insertion, during bladder examination, end of procedure and 15 minutes after operation. Method of measurement: Pulse Oxymetry.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHasti Hassani

Shahid Beheshti University of Medical Sciences

hasti62h@yahoo.com+98 21 2254 9029

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026